Celia Morgan
Clinical Psychopharmacologist
Data updated
Research Footprint
Celia Morgan appears in 10 tracked papers (2014–2025), most studied alongside Ketamine, Ayahuasca and MDMA, across Substance Use Disorders (SUD), Depressive Disorders and Alcohol Use Disorder (AUD).
Most-cited paper: Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder (164 citations).
Frequent co-authors: Will Lawn, Valerie Curran and David Nutt.
Background & Research
Celia J. A. Morgan is a clinical psychopharmacologist whose work spans experimental psychopharmacology, naturalistic studies and clinical trials focused on entactogens (MDMA/ecstasy) and dissociative agents (ketamine). She has led and contributed to multiple studies characterising the socio-emotional effects of MDMA — including empathy, cooperative behaviour and perception of trustworthiness — and has applied these mechanistic insights to clinical research on psychedelic-assisted treatments for substance use disorders.
Her recent research portfolio includes trials and qualitative studies investigating adjunctive ketamine with relapse-prevention psychological therapy for alcohol use disorder, and exploratory and Bayesian analyses of MDMA-assisted psychotherapy outcomes for alcohol use disorder. Morgan's methodological range — from lab-based behavioural pharmacology to randomised clinical trials and patient-centred qualitative work — has contributed to understanding both the acute interpersonal effects of entactogens and the therapeutic potential of these compounds in addiction psychiatry.
Key Impact
Notable for experimental and clinical research on MDMA/ecstasy effects on social cognition and for translating ketamine and MDMA-assisted approaches into treatments for alcohol use disorder.
Collaboration Network
17 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Celia Morgan is associated with.
University of Exeter
The University of Exeter is a public research university located in Exeter, England. It operates multiple campuses including Streatham and St Luke’s in Exeter and a campus at Penryn in Cornwall.
View stakeholder →Awakn Life Sciences
Public BiotechAwakn Life Sciences is a former UK-based biopharmaceutical company whose ketamine and esketamine alcohol-use-disorder assets were acquired by Solvonis Therapeutics in May 2025. Its lead programmes are now represented operationally by Solvonis as SVN-001 (IV ketamine plus CBT for severe AUD) and SVN-002 (esketamine oral thin film for US AUD). This record is retained for historical provenance of the Awakn-origin assets and source trail.
View stakeholder →